Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
暂无分享,去创建一个
Derick R. Peterson | J. Friedberg | R. Fisher | R. Coffman | D. Neuberg | J. Kutok | T. Mosmann | A. Freedman | P. Rothberg | D. Fisher | J. Liesveld | R. Salloum | D. Peterson | T. Brenn | J. Kelly | V. Dalton | P. Sims | D. Marquis | L. Rich | Elizabeth Ronan | Lynn Rich
[1] R. Coffman,et al. CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans , 2008, Clinical Cancer Research.
[2] C. Leichman,et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Rossi,et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. LaCasce,et al. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. , 2008, Seminars in hematology.
[5] J. Friedberg,et al. Monoclonal antibodies in lymphoma: the first decade. , 2008, Seminars in hematology.
[6] Arthur M. Krieg,et al. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.
[7] A. D. Van den Abbeele,et al. Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept , 2008, Leukemia & lymphoma.
[8] L. Gordon,et al. 253 T CELL MODULATION COMBINED WITH INTRATUMORAL INJECTIONS OF CPG OLIGODEOXYNUCLEOTIDES CURES LARGE AND SYSTEMIC LYMPHOMA TUMORS IN MICE , 2008 .
[9] J. Briones,et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. , 2008, Experimental hematology.
[10] J. Leonard,et al. Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[11] S. Akira,et al. Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 , 2007, The Journal of Immunology.
[12] J. Friedberg,et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. , 2007, Clinical immunology.
[13] B. Sander,et al. CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.
[14] D. Teachey,et al. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. , 2006, Blood.
[15] N. Ponzio,et al. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells. , 2006, International immunopharmacology.
[16] Marylène Lejeune,et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[18] A. Bossler,et al. Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.
[19] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[20] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Karey Shumansky,et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.
[22] C. Lynch,et al. Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Giese,et al. B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides , 2005, Clinical Cancer Research.
[25] J. Friedberg,et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. , 2005, Blood.
[26] J. Friedberg. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. , 2005, Hematology. American Society of Hematology. Education Program.
[27] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[28] J. Friedberg. Developing New Monoclonal Antibodies for Aggressive Lymphoma , 2004, Clinical Cancer Research.
[29] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[30] A. Difrancesco,et al. Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.
[31] W. Weng,et al. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Gribben,et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma , 2002, British journal of haematology.
[33] T. Habermann,et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. , 2002, Blood.
[34] M. Czuczman,et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Maloney,et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Kimberly,et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.
[38] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[39] J. Liesveld,et al. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage‐mediated antibody dependent cellular cytotoxicity , 1991, Journal of cellular biochemistry.
[40] R. Coffman,et al. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.